Last reviewed · How we verify
INNO-406
At a glance
| Generic name | INNO-406 |
|---|---|
| Sponsor | CytRx |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases (PHASE1)
- Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) (PHASE2)
- Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer (PHASE2)
- Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INNO-406 CI brief — competitive landscape report
- INNO-406 updates RSS · CI watch RSS
- CytRx portfolio CI